Develops innovative therapies for cancer treatment, focusing on immunotherapy approaches.
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company dedicated to advancing precision T cell therapies for the treatment of a wide range of medical conditions. The company's innovative approach focuses on developing off-the-shelf therapies designed to target infectious diseases, cancers, and neurological disorders with high precision and efficacy.
One of Tevogen Bio's key developments is TVGN 489, which has successfully completed a Phase 1 clinical trial. This therapy aims to address and prevent chronic lingering symptoms of diseases like Long COVID, as well as acute COVID-19 in specific patient populations such as those with B cell immune suppression, elderly patients, and individuals on T cell suppressing drugs. The company's pipeline also includes TVGN 601 for multiple sclerosis, TVGN 930 for Epstein-Barr virus associated lymphomas, TVGN 920 for cervical cancer, and TVGN 960 for mouth and throat cancer, highlighting its diverse therapeutic focus.
Founded in 2020 and headquartered in Warren, New Jersey, Tevogen Bio is at the forefront of leveraging advanced immunotherapy to tackle complex medical challenges. With a commitment to innovation and patient care, the company aims to transform treatment options and improve outcomes for patients worldwide.